Welcome to our dedicated page for Cellectis SEC filings (Ticker: CLLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cellectis S.A. (CLLS) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. Cellectis files its annual report on Form 20-F and furnishes current information on Form 6-K, which often include press releases, interim financial reports, and R&D presentations related to its gene-editing and cell therapy programs.
Through recent Form 6-K filings, Cellectis has submitted materials such as press releases announcing clinical data for lasme-cel (UCART22) in the BALLI-01 trial and eti-cel (UCART20x22) in the NATHALI-01 trial, technology updates on circular single-stranded DNA (CssDNA) for non-viral gene insertion, and details from its Investors R&D Day. Other 6-Ks have incorporated interim financial reports, including information on revenues, research and development expenses, and cash, cash equivalents, and fixed-term deposits.
Because Cellectis uses Form 20-F, investors can look to that filing for comprehensive annual information on its business, risk factors, financial statements, and governance. The series of Form 6-K reports complements the annual filing by providing more frequent updates on clinical progress, collaborations, arbitration outcomes, and capital markets activity.
On Stock Titan, these filings are paired with AI-powered summaries that explain the key points of each document in accessible language. Users can quickly understand what a particular 6-K or 20-F means for Cellectis’ allogeneic CAR-T pipeline, gene-editing platform, partnerships, and financial profile, without having to read every page of the original filing. Real-time updates from EDGAR help ensure that new Cellectis filings, including any future registration statements or amendments, are available as they are posted.
Cellectis S.A. filed a 6-K reporting new clinical data from the BALLI-01 Phase 1 study of lasme-cel (UCART22) in transplant-ineligible, relapsed/refractory B-ALL (3L+). The company states lasme-cel was generally well-tolerated with manageable cytokine release syndrome and neurotoxicity, and outlined a path to a pivotal Phase 2 study.
Activity signals were strongest with Cellectis-manufactured product (Process 2). In the P2 cohort, the overall response rate was 68% with 83% MRD-negativity among responders. Among 13 patients relapsed after prior CD22 therapy (inotuzumab), 31% achieved CR/CRi with MRD-negativity and all proceeded to HSCT. In a heavily pretreated subgroup that had three prior targeted therapies (n=22), 36% achieved MRD-negative CR/CRi. At the recommended Phase 2 dose (DL3; n=12), 7 had prior inotuzumab and 43% achieved MRD-negative CR/CRi, with all undergoing HSCT. The company plans to enroll the first patient in the pivotal Phase 2 in Q4 2025 and anticipates submitting a BLA in 2028.
Cellectis S.A. filed an amended Form 6-K/A to update its prior submission solely to provide the company’s unaudited interim financial statements in iXBRL format. The amendment covers the three- and six-month periods ended June 30, 2025 and is made in accordance with Rule 405 of Regulation S‑T and the Form 6‑K instructions.
The company states the amendment does not amend, revise, update, or restate other information in the original report. The materials are deemed incorporated by reference into Cellectis’s registration statements on Form F‑3 (Nos. 333‑284302, 333‑288491) and Form S‑8 (including Nos. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301).